Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan.
Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan.
Lancet Psychiatry. 2021 Jun;8(6):500-511. doi: 10.1016/S2215-0366(21)00077-8. Epub 2021 May 3.
Internet cognitive behavioural therapy (iCBT) is a viable delivery format of CBT for depression. However, iCBT programmes include training in a wide array of cognitive and behavioural skills via different delivery methods, and it remains unclear which of these components are more efficacious and for whom.
We did a systematic review and individual participant data component network meta-analysis (cNMA) of iCBT trials for depression. We searched PubMed, PsycINFO, Embase, and the Cochrane Library for randomised controlled trials (RCTs) published from database inception to Jan 1, 2019, that compared any form of iCBT against another or a control condition in the acute treatment of adults (aged ≥18 years) with depression. Studies with inpatients or patients with bipolar depression were excluded. We sought individual participant data from the original authors. When these data were unavailable, we used aggregate data. Two independent researchers identified the included components. The primary outcome was depression severity, expressed as incremental mean difference (iMD) in the Patient Health Questionnaire-9 (PHQ-9) scores when a component is added to a treatment. We developed a web app that estimates relative efficacies between any two combinations of components, given baseline patient characteristics. This study is registered in PROSPERO, CRD42018104683.
We identified 76 RCTs, including 48 trials contributing individual participant data (11 704 participants) and 28 trials with aggregate data (6474 participants). The participants' weighted mean age was 42·0 years and 12 406 (71%) of 17 521 reported were women. There was suggestive evidence that behavioural activation might be beneficial (iMD -1·83 [95% credible interval (CrI) -2·90 to -0·80]) and that relaxation might be harmful (1·20 [95% CrI 0·17 to 2·27]). Baseline severity emerged as the strongest prognostic factor for endpoint depression. Combining human and automated encouragement reduced dropouts from treatment (incremental odds ratio, 0·32 [95% CrI 0·13 to 0·93]). The risk of bias was low for the randomisation process, missing outcome data, or selection of reported results in most of the included studies, uncertain for deviation from intended interventions, and high for measurement of outcomes. There was moderate to high heterogeneity among the studies and their components.
The individual patient data cNMA revealed potentially helpful, less helpful, or harmful components and delivery formats for iCBT packages. iCBT packages aiming to be effective and efficient might choose to include beneficial components and exclude ones that are potentially detrimental. Our web app can facilitate shared decision making by therapist and patient in choosing their preferred iCBT package.
Japan Society for the Promotion of Science.
互联网认知行为疗法(iCBT)是一种可行的抑郁症认知行为疗法(CBT)的治疗方式。然而,iCBT 方案通过不同的传输方式包括对广泛的认知和行为技能的培训,目前仍不清楚这些组成部分中哪些更有效,哪些对谁更有效。
我们对抑郁症 iCBT 试验进行了系统回顾和个体参与者数据成分网络荟萃分析(cNMA)。我们检索了 PubMed、PsycINFO、Embase 和 Cochrane 图书馆,以获取从数据库开始到 2019 年 1 月 1 日发表的随机对照试验(RCT),这些 RCT 将任何形式的 iCBT 与急性治疗成人(年龄≥18 岁)的抑郁症的另一种 iCBT 或对照条件进行了比较。排除了住院患者或双相情感障碍患者的研究。我们向原始作者寻求个体参与者数据。当这些数据不可用时,我们使用汇总数据。两位独立的研究人员确定了纳入的成分。主要结局是使用患者健康问卷-9(PHQ-9)评分的增量均数差(iMD)表示,当一个成分添加到治疗中时。我们开发了一个网络应用程序,根据基线患者特征,估计任何两种成分组合之间的相对疗效。这项研究在 PROSPERO 中注册,CRD42018104683。
我们确定了 76 项 RCT,其中 48 项试验提供了个体参与者数据(11704 名参与者),28 项试验提供了汇总数据(6474 名参与者)。参与者的加权平均年龄为 42.0 岁,17521 名报告中 12406 名(71%)为女性。有证据表明,行为激活可能是有益的(iMD-1.83[95%可信区间(CrI)-2.90 至-0.80]),而放松可能是有害的(1.20[95% CrI 0.17 至 2.27])。基线严重程度是终点抑郁的最强预后因素。结合人和自动鼓励减少了治疗的辍学率(增量优势比,0.32[95% CrI 0.13 至 0.93])。大多数纳入研究的随机过程、缺失结局数据或报告结果的选择风险偏倚较低,偏离预期干预的风险不确定,结局测量的风险较高。研究之间及其成分存在中度至高度异质性。
个体参与者数据 cNMA 揭示了 iCBT 方案中潜在有益、无益或有害的组成部分和传递格式。旨在有效和高效的 iCBT 方案可能会选择包含有益的成分,并排除可能有害的成分。我们的网络应用程序可以通过治疗师和患者共同决策,帮助他们选择自己喜欢的 iCBT 方案。
日本学术振兴会。